Therapeutic Advances in Drug Safety

Papers
(The H4-Index of Therapeutic Advances in Drug Safety is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews53
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination27
Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance27
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review25
The danger of diazoxide in the neonatal intensive care unit22
Pharmacovigilance: reporting requirements throughout a product’s lifecycle21
The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review21
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge20
The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and 19
Anticholinergic burden measures and older people’s falls risk: a systematic prognostic review19
Definition of self-medication: a scoping review16
Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe15
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic13
Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis13
0.065096855163574